Erik van den Berg, CEO of Memo Therapeutics, shares his insights about leadership in biopharma and how Memo is working to develop antibodies to transform the lives of patients with viral infections and cancer.

Bruce Leuchter, CEO of Neurvati Neurosciences, shares his insights about leadership in biopharma and how Neurvati is working to advance drugs with the protentional to improve the health and lives of people living with neurological and psychiatric disorders.

Todd Harris, CEO of Tyra Biosciences, shares his insights about leadership in biopharma and how Tyra is working to develop precision medicines that target large fibroblast growth factor receptor biology.

Eduardo Bravo, CEO of Citryll, shares his insights about leadership in biopharma and how Citryll is working to transform the approach to treating immune mediated inflammatory diseases.

Abbas Kazimi, CEO of Nimbus Therapeutics, shares his insights about leadership in biopharma and how Nimbus is working to design and develop small molecule medicines capable of improving patients' lives.

Derek Adams, CEO of Stellular Bio, shares his insights about leadership in biopharma and how Stellular Bio is working to expand the reach of regenerative medicine.

Geoffrey Dow, CEO of 60 Degrees Pharmaceuticals, shares his insights about leadership in biopharma and how 60 Degrees Pharmaceuticals is working to develop vital medicines to treat and prevent infectious diseases.

Jorge Santos da Silva, co-founder and CEO of MoonLake Immunotherapeutics, shares his insights about leadership in biopharma and how MoonLake Immunotherapeutics is working to develop life changing therapies for people living with serious inflammatory diseases.

Vlad Vitoc, founder and CEO of MAIA Biotechnology, shares his insights with BioBoss host John Simboli about leadership in biopharma and how MAIA is working to develop and deliver innovative medicines to improve and extend the lives of people living with cancer.

“What leads a leader?”As you listen to clips from BioBoss podcasts, you may hear remarkably consistent ideas about leadership, as shared by BioBoss guests, who reflect on their younger years and how those experiences shaped their desire, and ability to lead.

BioBoss podcast host John Simboli reflects on Seasons 1-6 and invites listeners to Season 7 starting in January 2025

Sam Clark, founder and CEO of Terran Biosciences, shares his insights with BioBoss host John Simboli about leadership in biopharma and how Terran is working to develop therapeutics and technologies for patients with neurological and psychiatric diseases.

Iain Kilty, CEO of Sitryx, shares his insights about leadership in biopharma and how Sitryx is working to alter immune cell metabolism to resolve disease

Steve Uden, co-founder and CEO of RallyBio, shares his insights about leadership in biopharma and how Rallybio is working to to profoundly change the odds for patients living with rare diseases.

Karine Rossignol, co-founder and CEO of Smart Immune, shares her insights with BioBoss host John Simboli about leadership in biopharma and how Smart Immune is working to harness a patient's own thymus to re-arm the immune system against cancer and infection.

Erik Buntinx, founder and CEO of ANeuroTech, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how ANeurotech is working to develop effective treatments, with minimal or no side-effects, for patients who suffer with depression

Helen Torley, CEO of Halozyme Therapeutics, shares her thoughts with BioBoss host John Simboli about leadership in biopharma and how Halozyme is working to reinvent the patient experience by easing the burden of treatment and improving patient outcomes.

James Graham, CEO of Recce Pharmaceuticals, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Recce is working to develop a new class of synthetic anti-infectives designed to address the threat of antibiotic-resistant superbugs.

Mike Gaffney, CEO of Cellphire Therapeutics, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Cellphire is working to save lives by bringing novel hemostatic products to patients in need.

David Barmam, founder and CEO of Emendio Biotherapeutics, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Emendo is working to evolve traditional CRISPR tools and create new nucleases customized to any genetic disease.